alzheimers

so thinking biogen funds or acquires anavex

http://www.fool.com/investing/2016/06/27/3-reasons-anavex-stock-could-rise.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2

Biogen is currently running two identical phase 3 trials with its Alzheimer's hopeful, aducanumab, that are expected to enroll a combined 2,700 patients. The trials began last year and aren't expected to produce data concerning their main goal until 2020 and then fully complete a couple of years later. Biogen hasn't broken down exactly how much it's spending on this particular study, but it's probably a large part of the $2 billion it recorded in R&D expenses over the past 12 months. 

Anavex finished March with total assets of just $12.1 million and has yet to announce any partner willing to help it develop 2-73 for Alzheimer's. Without any products to sell, the only way it could fund a registrational trial is by selling its own shares, but that would rapidly shrink current investors' slice of any potential profits, if it's successful.